Resilience

Resilience is a North American contract development and manufacturing organization (CDMO) specializing in advanced therapies. The company provides high-quality, scalable manufacturing solutions, encompassing biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules. Resilience partners with leading biopharma entities to accelerate the market entry of complex medicines, emphasizing reliability and speed. Its strategic focus is on building a streamlined, high-performance network designed to address the dynamic requirements of clinical and commercial-stage innovators within the biotechnology, pharmaceuticals, and healthcare sectors.

Founded in 2020, Resilience operates with a significant workforce, estimated between 1,000 and 5,000 employees, across 3 locations. This scale supports its mission to deliver critical manufacturing services. The company's operational framework is geared towards efficiency and adaptability, serving a B2B market. Understanding the human capital behind these complex operations is key; Meet Resilience's team to gain insight into their leadership and expertise. Resilience leverages technology to enhance its manufacturing capabilities, positioning itself as a vital partner in the biopharmaceutical supply chain.

Resilience has demonstrated substantial financial growth and investment since its inception. The company reports revenue of $568.8M and has secured significant funding, including a $750M Series A, an $800M Series B, a $600M Series C, and a $625M Series D round, alongside substantial debt financing. This financial backing underscores its ambitious expansion and operational capacity. Its competitive landscape includes established players like AGC Biologics and KBI Biopharma. Explore financial highlights for detailed metrics on its funding and revenue.